UCB SA (UCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UCB SA (UCB) has a cash flow conversion efficiency ratio of 0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.52 Billion ≈ $1.78 Billion USD) by net assets (€10.87 Billion ≈ $12.70 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is UCB SA's balance sheet to measure how much of total assets are equity-financed.
UCB SA - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how UCB SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of UCB SA to evaluate the quality of earnings relative to operating cash generation.
UCB SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UCB SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E.ON SE
F:EOAA
|
0.141x |
|
E.ON SE
F:EOAN
|
0.141x |
|
Hangzhou Hikvision Digital Technology Co Ltd
SHE:002415
|
0.088x |
|
Exelon Corporation
NASDAQ:EXC
|
0.059x |
|
Diageo plc
MX:DEON
|
0.065x |
|
Sandvik AB
ST:SAND
|
0.046x |
|
Bank Central Asia Tbk
JK:BBCA
|
0.022x |
|
Orange S.A.
PA:ORA
|
0.212x |
Annual Cash Flow Conversion Efficiency for UCB SA (2000–2025)
The table below shows the annual cash flow conversion efficiency of UCB SA from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see UCB SA (UCB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.87 Billion ≈ $12.70 Billion |
€2.16 Billion ≈ $2.53 Billion |
0.199x | +60.72% |
| 2024-12-31 | €10.03 Billion ≈ $11.72 Billion |
€1.24 Billion ≈ $1.45 Billion |
0.124x | +46.05% |
| 2023-12-31 | €8.97 Billion ≈ $10.49 Billion |
€761.00 Million ≈ $889.69 Million |
0.085x | -31.32% |
| 2022-12-31 | €9.06 Billion ≈ $10.60 Billion |
€1.12 Billion ≈ $1.31 Billion |
0.123x | -33.34% |
| 2021-12-31 | €8.39 Billion ≈ $9.80 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.185x | +24.58% |
| 2020-12-31 | €7.27 Billion ≈ $8.50 Billion |
€1.08 Billion ≈ $1.26 Billion |
0.149x | +18.13% |
| 2019-12-31 | €7.01 Billion ≈ $8.19 Billion |
€882.00 Million ≈ $1.03 Billion |
0.126x | -27.72% |
| 2018-12-31 | €6.25 Billion ≈ $7.31 Billion |
€1.09 Billion ≈ $1.27 Billion |
0.174x | +7.73% |
| 2017-12-31 | €5.74 Billion ≈ $6.71 Billion |
€927.00 Million ≈ $1.08 Billion |
0.162x | +107.29% |
| 2016-12-31 | €5.48 Billion ≈ $6.40 Billion |
€427.00 Million ≈ $499.21 Million |
0.078x | +75.76% |
| 2015-12-31 | €5.55 Billion ≈ $6.48 Billion |
€246.00 Million ≈ $287.60 Million |
0.044x | -60.71% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€552.00 Million ≈ $645.35 Million |
0.113x | +69.44% |
| 2013-12-31 | €4.32 Billion ≈ $5.05 Billion |
€288.00 Million ≈ $336.70 Million |
0.067x | -13.81% |
| 2012-12-31 | €4.59 Billion ≈ $5.37 Billion |
€355.00 Million ≈ $415.03 Million |
0.077x | +27.66% |
| 2011-12-31 | €4.82 Billion ≈ $5.64 Billion |
€292.00 Million ≈ $341.38 Million |
0.061x | -45.06% |
| 2010-12-31 | €4.59 Billion ≈ $5.37 Billion |
€506.00 Million ≈ $591.57 Million |
0.110x | +64.99% |
| 2009-12-31 | €4.42 Billion ≈ $5.16 Billion |
€295.00 Million ≈ $344.89 Million |
0.067x | -26.70% |
| 2008-12-31 | €4.02 Billion ≈ $4.70 Billion |
€366.00 Million ≈ $427.89 Million |
0.091x | -20.71% |
| 2007-12-31 | €4.26 Billion ≈ $4.99 Billion |
€490.00 Million ≈ $572.86 Million |
0.115x | +71.05% |
| 2006-12-31 | €4.78 Billion ≈ $5.59 Billion |
€321.00 Million ≈ $375.28 Million |
0.067x | -44.19% |
| 2005-12-31 | €2.41 Billion ≈ $2.82 Billion |
€290.00 Million ≈ $339.04 Million |
0.120x | -67.06% |
| 2004-12-31 | €1.96 Billion ≈ $2.30 Billion |
€718.17 Million ≈ $839.61 Million |
0.365x | -3.84% |
| 2003-12-31 | €1.78 Billion ≈ $2.09 Billion |
€677.97 Million ≈ $792.61 Million |
0.380x | -0.34% |
| 2002-12-31 | €1.57 Billion ≈ $1.83 Billion |
€596.97 Million ≈ $697.92 Million |
0.381x | +11.99% |
| 2001-12-31 | €1.39 Billion ≈ $1.63 Billion |
€473.45 Million ≈ $553.51 Million |
0.341x | +18.59% |
| 2000-12-31 | €1.21 Billion ≈ $1.41 Billion |
€346.26 Million ≈ $404.81 Million |
0.287x | -- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more